

# Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

<https://marketpublishers.com/r/C136B6BCC8EEN.html>

Date: May 2016

Pages: 462

Price: US\$ 1,393.00 (Single User License)

ID: C136B6BCC8EEN

## Abstracts

This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 – 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R). Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.

The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.

Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

### **About Competitor Analysis Series:**

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

## Contents

### A) 2015 Sales of Therapeutic Antibodies

Overview: 2015 Biologics Sales per Class of Products

Overview: 2015 Therapeutic Antibody Sales per Class of Products

Blockbuster Therapeutic Antibodies in 2015

Anti-TNF Antibody Sales in 2015

Cancer Antibody Sales in 2015

Other Anti-Inflammatory Antibody Sales in 2015

Ophthalmic Antibody Sales in 2015

Cardiometabolic & Anti-Infective Antibody Sales in 2015

### B) Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

#### 1. Originator Anti-TNF Antibodies

Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets

2015 Sales of Anti-TNF Antibodies

Sales of Anti-TNF Antibodies in Q1/2016

Humira Pipeline of Recently Approved Indications & Upside Developments

Remicade Pipeline of Recent Approvals & Upside Indications

Enbrel Pipeline of Upside Indications

Simponi Pipeline of Recent Approvals & Upside Indications

Cimzia Pipeline of Recent Approvals & Upside Indications

Defense Strategies against Biosimilar Anti-TNF Antibodies

#### 2. Biosuperior Anti-TNF Antibodies

Non-Antibody Anti-TNF Biosuperiors

Anti-TNF Biosuperior Antibodies

#### 3. Biosimilar Anti-TNF Antibodies

Humira Biosimilar Antibodies:

Developments in Regulated Markets

Developments in Less Regulated Markets

Enbrel Biosimilar Antibodies:

Developments in Regulated Markets

Developments in Less Regulated Markets

Remicade Biosimilar Antibodies:

Developments in Regulated Markets

Developments in Less Regulated Market

Simponi & Cimzia Biosimilar Antibodies

### C) Biosimilar and Biosuperior Anti-VEGF/-R Antibodies – 2016 Update

#### 1) Marketed Anti-VEGF/R Products in Oncology

Avastin, Zaltrap & Cyramza Sales 2008 – 2015

- Avastin Sales and Indication Portfolio
- Zaltrap Sales and Indication Portfolio
- Cyramza Sales and Indication Portfolio
- 2) Anti-VEGF Biosuperiors of Avastin and Zaltrap
  - Anti-VEGF Biosuperior Pipeline in Oncology
  - Bispecific Anti-VEGF Pipeline in Oncology
- 3) Anti-VEGF-R Biosuperiors of Cyramza
  - Anti-VEGF-R Biosuperior Pipeline in Oncology
  - Bispecific Anti-VEGF-R Pipeline in Oncology
- 4) Avastin & Cyramza Biosimilar Pipeline in Oncology
- 5) Marketed Anti-VEGF Products in Ophthalmology
  - Lucentis & Eylea Sales 2008 – 2015
  - Lucentis Sales & Indication Portfolio
  - Eylea Sales & Indication Portfolio
- 6) Anti-VEGF Biosuperiors of Lucentis and Eylea
  - Biosuperior Anti-VEGF in Ophthalmology
  - Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology
- 7) Other Anti-VEGF Molecules in Ophthalmology
- 8) Lucentis Biosimilars in Ophthalmology
- 9) Eylea Biosimilars in Ophthalmology
- 10) Off-Label Use of Anti-VEGF in Ophthalmology
- D) Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update
  - 1. 2015 Anti-Her2 Antibody Sales
  - 2. Originator Anti-Her2 Antibodies
    - Herceptin Approved Indications & Pipeline
    - Perjeta Approved Indications & Pipeline
    - Kadcyla Approved Indications & Pipeline
  - 3. Biosuperior Anti-Her2 Antibodies
    - 3rd Generation Anti-Her2 Antibodies
    - Bispecific Anti-Her2 Antibodies
    - Anti-Her2 Antibody-Drug Conjugates, Immunotoxins, Immunocytokines & Radiopharmaceuticals
  - 4. Biosimilar Anti-Her2 Antibodies
    - Herceptin Biosimilar Antibodies
    - Developments in Regulated Markets
    - Development in Less Regulated Markets
  - 5. Perjeta Biosimilar Antibodies
- E) Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update
  - 1. 2015 Sales of Anti-CD20 Antibodies

2. Originator Anti-CD20 Antibodies
    - Rituxan / MabThera Approved Indications & Pipeline
    - Gazyva Approved Indications & Pipeline
    - Arzerra Approved Indications and R&D Pipeline
    - Zevalin Approved Indications
  3. Biosuperior Anti-CD20 Antibodies
    - 3rd Generation Anti-CD20 Antibodies
    - Bispecific Anti-CD20 Antibodies
    - Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines
  4. Biosimilar Anti-CD20 Antibodies
    - Rituxan/MabThera Biosimilar Antibodies:
      - Developments in Regulated Markets
      - Developments in Less Regulated Markets
  5. Arzerra Biosimilar Antibodies
- F) Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
1. Sales of Anti-EGF-R Antibodies
  2. Originator Anti-EGF-R Antibodies
    - Erbitux Approved Indications & Pipeline
    - Vectibix Approved Indications & Pipeline
    - Nimotuzumab Approved Indications & Pipeline
    - Portrazza Approved Indications & Pipeline
  3. Biosuperior Anti-EGF-R Antibodies
    - 3rd Generation Anti-EGF-R Antibodies
    - Bispecific Anti-EGF-R Antibodies
    - Anti-EGF-R Antibody Drug Conjugates
  4. Biosimilar Anti-EGF-R Antibodies
    - Erbitux Biosimilar Antibodies:
      - Developments in Regulated Markets
      - Developments in Less Regulated Markets
- G) Next Wave of Biosimilar Antibodies – 2016 Update
- Abatacept Biosimilar Antibodies
  - Aletuzumab Biosimilar Antibodies
  - Denosumab Biosimilar Antibodies
  - Eculizumab Biosimilar Antibodies
  - Omalizumab Biosimilar Antibodies
  - Palivizumab Biosimilar Antibodies
  - Tocilizumab Biosimilar Antibodies
  - Ustekinumab Biosimilar Antibodies
  - Biosimilars of Immune Checkpoint Inhibitor Antibodies

## H) Corporate Biosimilar & Biosuperior Therapeutic Antibody Pipelines

## I would like to order

Product name: Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

Product link: <https://marketpublishers.com/r/C136B6BCC8EEN.html>

Price: US\$ 1,393.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C136B6BCC8EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970